Chongqing Pharscin Pharmaceutical Co., Ltd. (SZSE: 002907)
Health Care · Pharmaceuticals · CN
CN¥14.26
-6.55% today · -22.5% 1Y
Chongqing Pharscin Pharmaceutical Co., Ltd. (SZSE: 002907) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $885.83M and employs 1,439 people.
Over the last twelve months the share price has lost 22.5%, trading between 11.42 and 18.73.
Tweenvest scores Chongqing Pharscin Pharmaceutical Co., Ltd. across four factors: quality 72/100, value 31/100, growth 24/100, dividend 43/100. Its strongest factor is quality.
002907 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $885.83M
- Revenue (TTM)
- $117.59M
- P/E
- 80.33
- EPS
- 0.18
- Dividend yield
- 0.53%
- Beta (5Y)
- -0.22
- 52-week high
- CN¥18.73
- 52-week low
- CN¥11.42
- Avg volume (3M)
- —
- Shares outstanding
- 417.60M
- Employees
- 1,439
- Next earnings
- —
About Chongqing Pharscin Pharmaceutical Co., Ltd.
Chongqing Pharscin Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company actively involved in the research, development, manufacturing, and distribution of medicines. Its product portfolio encompasses a broad spectrum of pharmaceutical formulations, such as tablets, powders, granules, hard and soft capsules, alongside various injectables including powder, freeze-dried powder, and small volume injections. The company also specializes in active pharmaceutical ingredient (API) synthesis. This diverse range of products targets critical therapeutic areas, including the central nervous system (CNS), digestive health, otolaryngology, oncology, as well as cardiovascular and cerebrovascular conditions. Established in 1996, the company maintains its headquarters in Chongqing, China.
- ISIN
- CNE100003308
- Founded
- 1996
- Listed since
- Oct 20, 2017
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,257.75 | +0.19% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.37 | +0.42% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $153.56 | +0.66% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.90 | -1.25% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.48 | -0.76% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.14 | +0.25% |
Figures last refreshed Aug 18, 2026.